Lacosamid Sandoz

Lacosamide, the active ingredient in Lacosamid Sandoz, is an anti‑epileptic presented as an oral formulation for oral use. It is used as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamid Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic that acts on focal seizure activity. - Partial‑onset seizures: adjunctive therapy to reduce seizure frequency. - Focal epilepsy: added to existing regimens to improve seizure control. - Epilepsy with focal onset: helps achieve better overall seizure management.

Lacosamide may cause a range of adverse reactions.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate upset stomach. - Headache: intermittent cranial discomfort. - Fatigue: feeling unusually tired. - Vision changes: blurred or double vision. - Tremor: fine shaking of hands or limbs.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive or suicidal ideation. - Hypersensitivity: anaphylaxis or severe allergic response.

Before prescribing Lacosamide, consider the following safety measures. - Cardiac monitoring: assess ECG for PR‑interval prolongation, especially in patients with cardiac disease. - Renal function: adjust use in severe renal impairment. - Hepatic function: evaluate liver enzymes in patients with hepatic disease. - Pregnancy: discuss potential risks with women of childbearing potential; data are limited. - Concomitant CNS depressants: monitor for additive central nervous system effects. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lacosamide can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma levels, decreasing efficacy. - Phenytoin: can lower lacosamide concentrations, compromising seizure control. - Anticonvulsants inducing CYP3A4: may markedly decrease lacosamide exposure.

Moderate Interactions (Monitor Closely): - Digoxin: lacosamide may increase digoxin levels; monitor cardiac function. - Warfarin: potential for altered INR; check coagulation parameters. - Alcohol: may enhance central nervous system depression, requiring caution.